Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist

Cardiovascular Research

Volumn 53, Issue 1, 2002, Pages 232-241

  Segev, Amit ^a,b   Aviezer, David ^c   Safran, Michal ^a   Gross, Zeev ^d   Yayon, Avner ^a,c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ProChon Biotech Ltd   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Growth factors; Restenosis; Smooth muscle

Indexed keywords

5,10,15,20 TETRAKIS(METHYL 4 PYRIDYL) 21H,23H PORPHINE TETRA(4 TOSYLATE); BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LIGAND; PLATELET DERIVED GROWTH FACTOR; PROTEOHEPARAN SULFATE; TOLUENESULFONIC ACID DERIVATIVE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOPLASTY; ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; ENZYME ACTIVATION; IC 50; INTIMA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RESTENOSIS; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0036136930     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00447-3     Document Type: Article

References (39)

1. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty
2. Restenosis after successful coronary angioplasty
3. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty
4. Remodeling of the coronary artery after vascular injury
5. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty
6. Multiple growth factors are released from mechanically injured vascular smooth muscle cells
7. Role of basic fibroblast growth factor in vascular lesion formation
8. The FGF family of growth factors and oncogenes
9. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study
10. Angiogenic growth factors
11. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
12. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation
13. Oligomerization reduces heparin affinity but enhances receptor binding of fibroblast growth factor 2
14. Structural basis for FGF receptor dimerization and activation
15. Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor
16. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells, II: Evidence for a pentasaccharide sequence that contain a 3-O-sulfate group
17. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis
18. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells
19. Identification of fibroblast growth factor 9 (FGF9) as a high affinity, heparin dependent ligand for FGF receptors 3 and 2 but not for FGF receptors 1 and 4
20. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
21. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor
22. Antisense c-myb oligonucleotides inhibit arterial smooth muscle accumulation in vivo
23. Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta-interferon
24. Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran
25. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
26. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury
27. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone
28. Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: Implications in the treatment of restenosis after angioplasty
29. Inhibitory effects of prostacyclin analogue, TFC-132, on aortic neointimal thickening in vivo and smooth muscle cell proliferation in vitro
30. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor
31. Differential structural requirements of heparin and heparan sulfate proteoglycans that promote bFGF-receptor binding
32. An essential heparin-binding domain in the fibroblast growth factor receptor kinase
33. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase
34. Structural interactions of fibroblast growth factor receptor with its ligands
35. Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vivo angiogenesis
36. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization
37. Cancer detection and therapy. Affinity of neoplastic tissues for porphyrins and metallo porphyrins
38. Controlled targeting of different subcellular sites by porphyrins in tumour-bearing mice
39. Photodynamic therapy